SEOM-GG clinical guidelines for the management of germ-cell testicular cancer (2023).

Testicular germ cell tumors are the most common tumors in adolescent and young men. They are curable malignancies that should be treated with curative intent, minimizing acute and long-term side effects. Inguinal orchiectomy is the main diagnostic procedure, and is also curative for most localized tumors, while patients with unfavorable risk factors for recurrence, or those who are unable or unwilling to undergo close follow-up, may require adjuvant treatment. Patients with persistent markers after orchiectomy or advanced disease at diagnosis should be staged and classified according to the IGCCCG prognostic classification. BEP is the most recommended chemotherapy, but other schedules such as EP or VIP may be used to avoid bleomycin in some patients. Efforts should be made to avoid unnecessary delays and dose reductions wherever possible. Insufficient marker decline after each cycle is associated with poor prognosis. Management of residual masses after chemotherapy differs between patients with seminoma and non-seminoma tumors. Patients at high risk of relapse, those with refractory tumors, or those who relapse after chemotherapy should be managed by multidisciplinary teams in experienced centers. Salvage treatment for these patients includes conventional-dose chemotherapy (TIP) and/or high-dose chemotherapy, although the best regimen and strategy for each subgroup of patients is not yet well established. In late recurrences, early complete surgical resection should be performed when feasible. Given the high cure rate of TGCT, oncologists should work with patients to prevent and identify potential long-term side effects of the treatment. The above recommendations also apply to extragonadal retroperitoneal and mediastinal tumors.

SEOM-GEICO clinical guideline on epithelial ovarian cancer (2023).

In recent years, the incorporation of new strategies to the therapeutic armamentarium has completely changed the outcomes of epithelial ovarian cancer (EOC). The identification of new predictive and prognostic biomarkers has also enabled the selection of those patients more likely to respond to targeted agents. Nevertheless, EOC is still a highly lethal disease and resistance to many of these new agents is common. The objective of this guideline is to summarize the most relevant strategies to manage EOC, to help the clinician throughout the challenging diagnostic and therapeutic processes and to provide evidence-based recommendations.

SEOM-GEMCAD-TTD clinical guideline for the diagnosis and treatment of gastric cancer (2023).

Gastric cancer (GC) is the fifth most common cancer worldwide with a varied geographic distribution and an aggressive behavior. In Spain, the incidence is lower and GC represents the tenth most frequent tumor and the seventh cause of cancer mortality. Molecular biology knowledge allowed to better profile patients for a personalized therapeutic approach. In the localized setting, the multidisciplinary team discussion is fundamental for planning the therapeutic approach. Endoscopic resection in very early stage, perioperative chemotherapy in locally advanced tumors, and chemoradiation + surgery + adjuvant immunotherapy for the GEJ are current standards. For the metastatic setting, biomarker profiling including Her2, PD-L1, MSS status is needed. Chemotherapy in combination with checkpoint inhibitors had improved the outcomes for patients with PD-L1 expression. Her2 positive patients should receive antiHer2 therapy added to chemotherapy. We describe the different evidences and recommendations based on the literature.

Update on the management of older patients with pancreatic adenocarcinoma: a perspective from medical oncology.

In the context of pancreatic cancer, surgical intervention is typically recommended for localized tumours, whereas chemotherapy is the preferred approach in the advanced and/or metastatic setting. However, pancreatic cancer is closely linked to ageing, with an average diagnosis at 72 years. Paradoxically, despite its increased occurrence among older individuals, this population is often underrepresented in clinical studies, complicating the decision-making process. Age alone should not determine the therapeutic strategy but, given the high comorbidity and mortality of this disease, a comprehensive geriatric assessment (CGA) is necessary to define the best treatment, prevent toxicity, and optimize older patient care. In this review, a group of experts from the Oncogeriatrics Section of the Spanish Society of Medical Oncology (Sociedad Española de Oncología Médica, SEOM), the Spanish Cooperative Group for the Treatment of Digestive Tumours (Grupo Español de Tratamiento de los Tumores Digestivos, TTD), and the Multidisciplinary Spanish Group of Digestive Cancer (Grupo Español Multidisciplinar en Cáncer Digestivo, GEMCAD) have assessed the available scientific evidence and propose a series of recommendations on the management and treatment of the older population with pancreatic cancer.

Eventos adversos da hipodermóclise em pacientes oncológicos sob cuidados paliativos: revisão de escopo / Adverse events of hypodermoclysis in cancer patients under palliative care: scoping review / Eventos adversos de la hipodermoclisis en pacientes con cáncer bajo cuidados paliativos: revisión del alcance

Objetivo: mapear as evidências científicas sobre os eventos adversos locais decorrentes do uso da hipodermóclise em pacientes oncológicos sob cuidados paliativos. Método: revisão de escopo baseada nas diretrizes Prisma, cuja busca foi realizada nas bases de dados: Portal Regional da Biblioteca Virtual em Saúde; National Library of Medicine; Cochrane Library, Scopus, Web of Science e Embase via Portal de periódicos da Capes. Resultados: Os eventos adversos mais citados nos estudos foram eritema, edema, desconforto no local, abcesso e sangramento. Considerações finais: a hipodermóclise é uma técnica útil e segura para hidratação e administração de medicamentos em pacientes oncológicos em cuidados paliativos, porém apresenta eventos adversos que precisam ser mais bem esclarecidos.

Objective: to map the scientific evidence on local adverse events resulting from the use of hypodermoclysis in cancer patients un-der palliative care. Method: scoping review based on the Prisma guidelines, whose search was carried out in the databases: Regional Portal of the Virtual Health Library; National Library of Medicine; Cochrane Library, Scopus, Web of Science and Embase via Capes Journal Portal. Results: The adverse events most cited in the studies were erythema, edema, local discomfort, abscess and bleeding. Final considerations: hypodermoclysis is a useful and safe technique for hydration and medication administration in cancer pa-tients undergoing palliative care, but it presents adverse events that need to be better clarified.

Objetivo: mapear la evidencia científica sobre eventos adversos locales resultantes del uso de hipodermoclisis en pacientes con cán-cer en cuidados paliativos. Método: revisión de alcance basada en los lineamientos Prisma, cuya búsqueda se realizó en las bases de datos: Portal Regional de la Biblioteca Virtual en Salud; Biblioteca Nacional de Medicina; Biblioteca Cochrane, Scopus, Web of Science y Embase vía Capes Journal Portal. Resultados: Los eventos adversos más citados en los estudios fueron eritema, edema, malestar local, absceso y sangrado. Consideraciones finales: la hipodermoclisis es una técnica útil y segura para la hidratación y administración de medicamentos en pacientes oncológicos sometidos a cuidados paliativos, pero presenta eventos adversos que necesitan ser mejor esclarecidos.

Avances y desafíos locales en el diagnóstico molecular de tumores sólidos: una mirada sanitaria hacia la oncología de precisión en Chile / Local advances and challenges in the molecular diagnosis of solid tumors: a health perspective towards precision oncology in Chile

El cáncer seguirá siendo uno de los mayores desafíos para la salud pública a nivel local y mundial. Actualmente, en nuestro país, el cáncer es la principal causa de muerte. Gracias al enorme conocimiento acumulado en las últimas décadas sobre las bases celulares y moleculares del cáncer, se ha desarrollado la oncología de precisión, un enfoque que permite dirigir de manera cada vez más precisa el tratamiento farmacológico en función de los exámenes de diagnóstico. Para ello se utilizan tecnologías avanzadas, como la secuenciación de próxima generación. Es imprescindible implementar estas tecnologías en los sistemas sanitarios actuales y futuros para optimizar el arsenal de estrategias para el control del cáncer. En esta revisión, se discuten algunos alcances de la oncología de precisión, especialmente aplicada a tumores sólidos. Se aborda el estado del arte de los biomarcadores mínimos necesarios para el diagnóstico de este importante grupo de neoplasias, la situación local en cuanto a las capacidades tecnológicas instaladas en el territorio nacional ya sea con fines de investigación o diagnóstico, y el potencial impacto sanitario que tendría la aplicación de todo este conocimiento práctico al servicio de las personas con cáncer, tanto en el sector público como privado.

Cancer will remain one of the most significant challenges for public health, locally and globally. Currently, cancer is the leading cause of death in our country. Thanks to the enormous knowledge accumulated in recent decades on the cellular and molecular bases of cancer, precision oncology has been developed, an approach that allows for increasingly precise pharmacological treatment based on diagnostic tests. Advanced technologies such as next-generation sequencing are used for this purpose. It is essential to implement these technologies in current and future health systems to optimize the arsenal of strategies for cancer control. This review discusses some of the achievements of precision oncology, particularly applied to solid tumors. It addresses the state-of-the-art minimum biomarkers required for the diagnosis of this important group of neoplasms, the local situation regarding technological capabilities installed in the national territory, either for research or diagnosis, and the potential health impact of applying all this practical knowledge to serve people with cancer, both in the public and private sectors.

Physical Examination in Medical Oncology Guiding the Development of a Protocol for Teleoncology Care in a Public Health Care Oncology Service.

PURPOSE: We aimed to define clinical variables that could predict changes in physical examination (PE) findings and consequently lead to significant differences in clinical management. This knowledge is important because of the growing popularity of teleoncology consultations, in which there is no possibility of PE, aside from inspection. METHODS: This prospective study was conducted in two public hospitals in Brazil. Clinical variables and findings of PE, as well as the management plan determined at the end of the medical appointment, were systematically recorded. RESULTS: A total of 368 in-person clinical evaluations of patients with cancer were included. PE was normal or had alterations already seen in previous consultations in 87% of the cases. Among patients with new changes in PE (n = 49), cancer treatment was maintained in 59%, complementary examinations and specialist appointments were requested in 31%, and oncological therapy was modified directly after PE in 10%. Of the total 368 visits, only 12 (3%) had a change in oncological management, five directly after PE abnormalities and 7 after complementary assessment. The presence of symptoms and reasons for consultation other than follow-up showed a positive association with alterations in PE and consequent changes in clinical management by univariate and multivariate analysis (P < .05). CONCLUSION: Considering changes in clinical management, PE on every encounter for medical oncology surveillance visits may not be necessary. We envision that teleoncology will be a safe modality in most cases, given the large percentage of asymptomatic patients with no changes in PE during face-to-face care. However, for patients with advanced disease and symptoms, however, we suggest priority for in-person care.

[Local advances and challenges in the molecular diagnosis of solid tumors: a health perspective towards precision oncology in Chile]. / Avances y desafíos locales en el diagnóstico molecular de tumores sólidos: una mirada sanitaria hacia la oncología de precisión en Chile.

Cancer will remain one of the most significant challenges for public health, locally and globally. Currently, cancer is the leading cause of death in our country. Thanks to the enormous knowledge accumulated in recent decades on the cellular and molecular bases of cancer, precision oncology has been developed, an approach that allows for increasingly precise pharmacological treatment based on diagnostic tests. Advanced technologies such as next-generation sequencing are used for this purpose. It is essential to implement these technologies in current and future health systems to optimize the arsenal of strategies for cancer control. This review discusses some of the achievements of precision oncology, particularly applied to solid tumors. It addresses the state-of-the-art minimum biomarkers required for the diagnosis of this important group of neoplasms, the local situation regarding technological capabilities installed in the national territory, either for research or diagnosis, and the potential health impact of applying all this practical knowledge to serve people with cancer, both in the public and private sectors.

Estrategias del equipo de salud para afrontar la muerte de niños y adolescentes con cáncer / Strategies by the Health Team for Coping with the Death of Children and Adolescents with Cancer

Introducción: La muerte en niños y adolescentes por cáncer suele ser difícil de afrontar por los profesionales de salud. Si no cuentan con modos adecuados para transitar estos duelos, pueden generarse problemas psicológicos, emocionales y físicos, exponiéndose a Burnout. Objetivo: Develar las estrategias utilizadas por profesionales y técnicos de salud de hospitales públicos chilenos para afrontar la muerte de infantes con cáncer. Métodos: Investigación cualitativa fenomenológica, realizada en cinco hospitales públicos en Santiago de Chile, entre mayo-septiembre del 2017. Población de 37 profesionales y técnicos de salud que vivenciaron morir niños y adolescentes con cáncer. Se efectuaron entrevistas en profundidad, guiadas por la pregunta "¿Cómo ha afrontado usted la muerte de los pacientes en su unidad?" Las narrativas se transcribieron y analizaron según las etapas de Streubert, se triangularon los datos hasta alcanzar la saturación. Resultados: Las principales estrategias fueron participar de ritos de despedida ante la muerte, realizar actividades recreativas con miembros del equipo fuera de la jornada laboral, hacer cambios en la rutina de trabajo, separar aspectos personales y profesionales. Al percibir un bajo apoyo de la institución, propusieron facilitar la asistencia al funeral, desarrollar intervenciones formales de apoyo en duelo, realizar intervenciones de autocuidado e incorporar el tema de la muerte en las inducciones laborales. Conclusión: Los profesionales y técnicos cuentan con estrategias para afrontar sus duelos. Sin embargo, requieren de apoyo formal de la institución, junto con capacitación continua en la temática. Es fundamental que la institución se implique en esta problemática(AU)

Introduction: Cancer deaths among children and adolescents are often difficult for health professionals to cope with. If they do not have adequate ways to deal with this grief, psychological, emotional and physical problems may arise, exposing them to burnout or the so called burned-out worker syndrome. Objective: To reveal the strategies used by health professionals and technicians in Chilean public hospitals to cope with the death of children with cancer. Methods: Qualitative and phenomenological research carried out in five public hospitals in Santiago, Chile, between May and September 2017. The population was made up of 37 health professionals and technicians who experienced the death of children and adolescents with cancer. In-depth interviews were conducted, guided by the following question: How have you coped with the death of patients in your unit? The narratives were transcribed and analyzed according to the stages described by Streubert. In addition, the data were triangulated until saturation was reached. Results: The main strategies were to participate in farewell rites in the face of death, to carry out recreational activities with team members outside the workday, to make changes in the work routine, as well as to separate personal and professional aspects. When perceiving low support from the institution, they proposed facilitating attendance at the funeral, developing formal bereavement support interventions, carrying out self-care, and incorporating the matter of death into work inductions. Conclusion: Professionals and technicians have strategies to cope with their bereavement. However, they need formal support from the institution, together with continuous training on the matter. It is essential for the institution to become involved in this issue(AU)

Importancia de la valoración perioperatoria en el paciente oncológico / Importance of perioperative evaluation in cancer patients

The importance of preoperative anesthetic evaluation in a cancer patient is indispensable. Enables the anesthesiologist and surgical team to realize whether the clinical status can be optimized or if a specific perioperative approach is required. However, with proper evaluation, the goal of prompt surgical therapy should be kept in mind. In cancer patients, the diagnostic approach is not far from the usual preoperative evaluation performed on any surgical patient, which focuses on medical comorbidities and current functional capacity. Nevertheless, in these patients, it becomes relevant to recognize the mass anatomical location, the compromise of adjacent structures, and the mass effects that the tumor may be causing. Also, it is essential to assess the nutritional status and patients' metabolic or neurohormonal consequences. On the other hand, the oncological disease itself or its associated therapies may trigger secondary organic repercussions that impact anesthetic management and perioperative care. All of which deserves meticulous surgical planning. Acknowledging these factors will enable us to face cancer surgery better, understand and reduce perioperative risks, and promote accelerated recovery.

La importancia de la evaluación preoperatoria anestésica en un paciente oncológico es relevante a la hora de detectar y conocer condiciones que puedan ser optimizadas o que requieran un manejo específico durante el perioperatorio, sin que esto retrase la oportuna entrega de la terapia definitiva, sea ésta cirugía, quimioterapia o radioterapia. Si bien este enfrentamiento no dista mucho de la evaluación preoperatoria habitual que se realiza a cualquier paciente quirúrgico, hay que dar relevancia en conocer el estado funcional actual y al estado nutricional con el que se presenta el paciente, así como sus condiciones médicas asociadas. También es importante los efectos de masa que puede estar provocando el tumor, su ubicación anatómica, el compromiso de otras estructuras y su funcionalidad, si es que la tiene. Por efecto de la propia enfermedad oncológica o de las terapias médicas y quirúrgicas, pueden presentarse alteraciones hematológicas y metabólicas importantes, que requieren manejos específicos y compensaciones previas, así como las repercusiones orgánicas e interacciones anestésicas que pueden tener las terapias neo- adyuvantes para una correcta y meticulosa planificación quirúrgica. El conocer estos factores nos posibilitará enfrentarnos de mejor manera a la cirugía oncológica, conocer y disminuir los riesgos perioperatorios, y favorecer una recuperación acelerada con menor tasa de complicaciones.

Do the Potential Medical Benefits of Phase 1 Pediatric Oncology Trials Justify the Risks? Views of the United States Public.

OBJECTIVES: To assess the US public's views on whether the potential medical benefits of phase 1 pediatric oncology trials justify the risks. STUDY DESIGN: Online survey of a nationally representative sample of US adults. Participants were presented with a hypothetical scenario in which they have a 10-year-old child with advanced cancer. They were then offered the option of giving their child supportive care or trying one more potential treatment, in the research or clinical care setting, which has the same risks and potential medical benefits as the average phase 1 pediatric oncology trial. We assessed what percentage of respondents thought the potential medical benefits justify the risks. RESULTS: In total, 1658 of the 2508 individuals who were sent the survey participated (response rate = 66.1%). Of those who passed all 3 test questions indicating understanding, 67.1% in the research scenario and 58.5% in the clinical care scenario regarded the potential medical benefits of an average phase 1 pediatric oncology trial as equal to or greater than the risks. In addition, 53.4% of respondents in the research scenario thought it was appropriate for researchers to conduct a study in children with these risks and potential medical benefits, and 46.9% stated they would enroll their own child in such a trial. CONCLUSIONS: A majority of the US public regards the potential medical benefits of average phase 1 pediatric oncology trials as justifying the risks. This finding suggests that these trials are ethically appropriate and approvable in patients who have no more effective treatment options. At the same time, a significant minority thought the potential medical benefits do not justify the risks, suggesting these trials should be approved only when they have significant social value. Moreover, approximately one-half of respondents regarded the trials as inappropriate and would not enroll their own child, underscoring the need for a rigorous informed consent process that accurately educates parents regarding the risks, potential medical benefits, and alternatives, so they can decide whether to enroll their child based on their own preferences and goals.

PARP1 Is Overexpressed in Hematological Malignant Cell Lines: A Framework for Experimental Oncology.

BACKGROUND/AIM: Experimental oncology commonly uses cells as oncological models, providing a framework for the testing of drugs, and investigation of cytotoxicity, mutagenesis and carcinogenesis. Investigations into poly-ADP-ribose polymerase 1 (PARP1) inhibition have become ever more relevant due to its approval as a therapeutic option for tumors with BRCA1/2 DNA repair-associated mutation and the seemingly high PARP expression levels in some tumor subtypes. In this study, we aimed to determine PARP1 gene expression of different hematological cancer-derived cell lineages and compare them to that of normal cell lines. MATERIALS AND METHODS: PARP1 gene expression in seven different neoplastic lineages, representing three different hematological disorders (chronic myeloid leukemia, Burkitt lymphoma and acute lymphoblastic leukemia), was quantified by quantitative real-time polymerase chain reaction. RESULTS: All hematological malignant lineages in this study overexpressed PARP1 when compared to the normal cell line MRC-5, with Burkitt's lymphoma cells having the highest expression values (fold change: 93). CONCLUSION: Overexpression of PARP1 in hematological malignant lineages is a finding of crucial importance to future studies exploring possible cellular oncogenic pathways and supports investigations into the effectiveness of PARP1 inhibitors against hematological disorders.

Management of coping with the risks of COVID-19 in an onco-hematological outpatient clinic: an experience report.

OBJECTIVE: to describe the experience of a private outpatient network for hematology and oncology treatment in the adoption of management tools to face the risk of contamination by SARS-CoV-2. METHOD: an experience report on the use of a root cause analysis method to identify potential risks of contamination by COVID-19 among patients and employees. Through the risks identified through the Ishikawa Diagram, we built an action plan, linked to the 5W2H tool, for planning and decision-making implemented. RESULTS: the number of attendances in person and people circulating in the units was reduced, protective distance measures and new protection barriers were fundamental to control the risks of spreading COVID-19 in patients and employees. FINAL CONSIDERATIONS: the management tools served as a valuable tool in the construction of measures, making the measures in question more clearly and applicable.

Use of real-world evidence for oncology clinical decision making in emerging economies.

Real-world evidence (RWE) can provide insights into patient profiles, disease detection, treatment choice, dosing strategies, treatment sequencing, adverse event management and financial toxicity associated with oncology treatment. However, the full potential of RWE is untapped in emerging economies due to structural and behavioral factors. Structural barriers include lack of regulatory engagement, real-world data availability, quality and integrity. Behavioral barriers include entrenched healthcare professional behaviors that impede rapid RWE understanding and adoption. These barriers can be addressed with close collaboration of healthcare stakeholders; of whom, regulators need to be at the forefront given their ability to facilitate use of RWE in healthcare policy and legislation.

Lay abstract Traditionally, randomized clinical trials have been used to provide insights on new medical therapies and continue to remain the gold standard for approval. The-increasing availability of patient level data in the real-world, it is now possible to generate evidence regarding the usage and potential benefits or risks of a medical therapy derived from analysis of real-world data. This evidence is collectively referred to real-world evidence (RWE). randomized clinical trials and RWE are complementary and the area of Oncology especially benefits from RWE to guide clinical decision making across the patient journey. Key benefits include cancer screening and diagnosis, optimal treatment choices (including personalized medicine) and disease management such as dosing and treatment of side effects. In recent times, RWE generation in oncology has been prolific in the USA and western Europe. With expansive biopharmaceutical investments into infrastructure harnessing patient-level data and greater local regulatory guidance, oncology patients in emerging economies may now also have the opportunity to benefit from clinical decision making informed by RWE.

The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Management of Metastatic and/or Unresectable Pheochromocytoma and Paraganglioma.

ABSTRACT: This manuscript is the result of the North American Neuroendocrine Tumor Society consensus conference on the medical management and surveillance of metastatic and unresectable pheochromocytoma and paraganglioma held on October 2 and 3, 2019. The panelists consisted of endocrinologists, medical oncologists, surgeons, radiologists/nuclear medicine physicians, nephrologists, pathologists, and radiation oncologists. The panelists performed a literature review on a series of questions regarding the medical management of metastatic and unresectable pheochromocytoma and paraganglioma as well as questions regarding surveillance after resection. The panelists voted on controversial topics, and final recommendations were sent to all panel members for final approval.

Treating Acute Leukemia During the COVID-19 Pandemic in an Environment With Limited Resources: A Multicenter Experience in Four Latin American Countries.

PURPOSE: The COVID-19 pandemic is a colossal challenge for global health; nonetheless, specific subgroups face considerably higher risks for infection and mortality. Among patients with malignant diseases, those with hematologic neoplasms are at a higher risk for poor outcomes. The objective of this study was to register treatment modifications associated with the COVID-19 pandemic and their short-term consequences in Latin America. METHODS: Multicenter, prospective, observational, cohort study including patients older than 14 years from 14 centers in four countries (Mexico, Peru, Guatemala, and Panama) who had a confirmed diagnosis of acute leukemia, and who were undergoing active treatment since the first COVID-19 case in each country until the cutoff on July 15, 2020. RESULTS: We recruited 635 patients. Treatment modifications because of the COVID-19 pandemic were reported in 40.8% of cases. The main reason for such modifications was logistic issues (55.0%) and the most frequent modification was chemotherapy delay (42.0%). A total of 13.1% patients developed COVID-19 disease, with a mortality of 37.7%. Several factors were identified as independently associated with mortality, including a diagnosis of acute myeloid leukemia (odds ratio 2.38 [95% CI, 1.47 to 3.84]; P < .001), while the use of telemedicine was identified as a protective factor (odds ratio 0.36 [95% CI, 0.18 to 0.82]; P = .014). CONCLUSION: These results highlight the collateral damage of COVID-19 in oncology patients.

Impact of clinical pharmacy in oncology and hematology centers: A systematic review.

BACKGROUND: Oncology and hematology is a complex and specific area that requires monitoring by a multidisciplinary team capable of personalizing the treatment of each patient. Clinical pharmacy services have the potential to contribute significantly to the effective and economical care of cancer patients. OBJECTIVE: To evaluate, synthesize and critically present the available evidence on the impact of the Clinical Pharmacy in the treatment of patients with hematological cancer. METHOD: A review was carried out on the bases PubMed/MEDLINE, LILACS and Google Scholar. The included studies were: studies that evaluated the effects of pharmaceutical interventions in clinical in oncology and hematology services and having as a population patient with hematological cancer. RESULTS: 17 studies were selected among 745 identified. 4.771 patients were included, with an average follow-up time of 15.3 months. Patients affected by some type of hematological cancer, undergoing chemotherapy treatment, showed better adherence and continuity when accompanied by a clinical pharmacist, added to this professional in carrying out interventions, provides control of symptoms such as cancer pain, nausea and constipation and, thus, contributes to decrease the length of hospital stay. CONCLUSION: The implementation of a Clinical Pharmacy service in oncology and hematology centers contributes significantly to the effectiveness of pharmacotherapeutic treatment, treatment costs reduction, safety increase in the use of medications and the patient's quality of life.

Association Between a National Insurer's Pay-for-Performance Program for Oncology and Changes in Prescribing of Evidence-Based Cancer Drugs and Spending.

PURPOSE: Cancer drug prescribing by medical oncologists accounts for the greatest variation in practice and the largest portion of spending on cancer care. We evaluated the association between a national commercial insurer's ongoing pay-for-performance (P4P) program for oncology and changes in the prescribing of evidence-based cancer drugs and spending. METHODS: We conducted an observational difference-in-differences study using administrative claims data covering 6.7% of US adults. We leveraged the geographically staggered, time-varying rollout of the P4P program to simulate a stepped-wedge study design. We included patients age 18 years or older with breast, colon, or lung cancer who were prescribed cancer drug regimens by 1,867 participating oncologists between 2013 and 2017. The exposure was a time-varying dichotomous variable equal to 1 for patients who were prescribed a cancer drug regimen after the P4P program was offered. The primary outcome was whether a patient's drug regimen was a program-endorsed, evidence-based regimen. We also evaluated spending over a 6-month episode period. RESULTS: The P4P program was associated with an increase in evidence-based regimen prescribing from 57.1% of patients in the preintervention period to 62.2% in the intervention period, for a difference of +5.1 percentage point (95% CI, 3.0 percentage points to 7.2 percentage points; P < .001). The P4P program was also associated with a differential $3,339 (95% CI, $1,121 to $5,557; P = .003) increase in cancer drug spending and a differential $253 (95% CI, $100 to $406; P = .001) increase in patient out-of-pocket spending, but no significant changes in total health care spending ($2,772; 95% CI, -$181 to $5,725; P = .07) over the 6-month episode period. CONCLUSION: P4P programs may be effective in increasing evidence-based cancer drug prescribing, but may not yield cost savings.